Valcyte (Valganciclovir)
Antiviral medicine used to treat and prevent cytomegalovirus (CMV) infections
Quick Facts About Valcyte
Key Takeaways About Valcyte
- Primary uses: Valcyte treats CMV retinitis in AIDS patients and prevents CMV disease after organ transplantation
- Prodrug advantage: Valganciclovir provides approximately 10 times better oral bioavailability than ganciclovir, making effective oral therapy possible
- Blood monitoring is essential: Regular complete blood counts are required due to the risk of severe bone marrow suppression (neutropenia, anemia, thrombocytopenia)
- Contraindicated in pregnancy: Women must use effective contraception during treatment and for 30 days after; men must use condoms for 90 days after stopping
- Take with food: Valcyte should always be taken with food to maximize absorption and achieve therapeutic drug levels
What Is Valcyte and What Is It Used For?
Valcyte (valganciclovir) is an antiviral medicine that belongs to a class of drugs known as nucleoside analogues. It works by preventing a virus called cytomegalovirus (CMV) from multiplying and attacking healthy cells. It is available as 450 mg film-coated tablets and as a powder for oral solution (50 mg/ml).
Valganciclovir, the active ingredient in Valcyte, is a prodrug that is rapidly converted in the body to ganciclovir after oral administration. Ganciclovir then undergoes phosphorylation within virus-infected cells, ultimately forming ganciclovir triphosphate. This active metabolite competitively inhibits viral DNA polymerase and is incorporated into the growing viral DNA chain, causing chain termination and effectively halting CMV replication.
Cytomegalovirus is a member of the herpes virus family and is remarkably common – studies indicate that between 50% and 80% of adults worldwide carry the virus. In people with healthy immune systems, CMV typically causes no symptoms or only mild illness. However, in individuals with weakened immune systems – such as those with AIDS or organ transplant recipients taking immunosuppressive medications – CMV can cause serious, life-threatening infections affecting the eyes, lungs, gastrointestinal tract, and other organs.
Valcyte is specifically approved for two main clinical indications. First, it is used for the treatment of CMV retinitis in adult patients with acquired immunodeficiency syndrome (AIDS). CMV retinitis is an infection of the retina that can cause progressive vision loss and, if left untreated, blindness. Second, Valcyte is indicated for the prevention (prophylaxis) of CMV disease in both adult and pediatric organ transplant recipients who are at risk of developing CMV infection – particularly those who have received an organ from a CMV-positive donor while being CMV-negative themselves (known as donor-positive/recipient-negative, or D+/R- serostatus).
The development of valganciclovir represented a significant advance in antiviral therapy. Before its introduction, treatment of CMV infections largely required intravenous ganciclovir, which necessitated hospital admission and central venous access. Oral ganciclovir was available but had very poor bioavailability (approximately 6%). Valganciclovir achieves oral bioavailability of approximately 60%, delivering ganciclovir blood levels comparable to those achieved with intravenous ganciclovir, thereby enabling effective outpatient oral therapy for CMV disease.
What Should You Know Before Taking Valcyte?
Valcyte is contraindicated in patients with known hypersensitivity to valganciclovir or ganciclovir, and in breastfeeding women. Special caution is required in patients with low blood cell counts, kidney problems, or those taking other bone marrow-suppressive medications. Regular blood monitoring is mandatory throughout treatment.
Contraindications
You must not take Valcyte if you are allergic (hypersensitive) to valganciclovir, ganciclovir, or any of the other ingredients in the formulation. Because valganciclovir is converted directly to ganciclovir in the body, anyone with a known allergy to ganciclovir should also avoid Valcyte. Additionally, you should inform your physician if you are allergic to aciclovir, penciclovir, valaciclovir, or famciclovir, as these are chemically related antiviral agents and cross-sensitivity may occur.
Valcyte is contraindicated during breastfeeding. If your physician determines that Valcyte treatment is necessary, you must stop breastfeeding before beginning the medication, as the drug may pass into breast milk and harm the nursing infant.
Warnings and Precautions
Before starting Valcyte, tell your doctor about all of your medical conditions, particularly if you have any of the following:
- Low blood cell counts: If you have low white blood cell counts (neutropenia), low red blood cell counts (anemia), or low platelet counts (thrombocytopenia), your doctor will perform blood tests before starting treatment and will continue to monitor your blood counts regularly throughout therapy. Valcyte can further suppress bone marrow function, potentially causing dangerous drops in blood cell levels.
- Kidney problems: Ganciclovir (the active metabolite of valganciclovir) is eliminated primarily through the kidneys. If your kidneys are not functioning normally, your doctor may need to prescribe a lower dose and monitor your kidney function and blood counts more frequently during treatment.
- Radiation therapy: If you are undergoing or have recently completed radiation therapy, the combined bone marrow-suppressive effects may increase the risk of severe blood count abnormalities.
Valcyte can cause severe bone marrow suppression, leading to dangerously low levels of white blood cells, red blood cells, and platelets. This can increase your risk of serious infections, anemia, and bleeding. Your doctor must perform regular blood tests throughout your treatment. Contact your healthcare provider immediately if you develop signs of infection (fever, sore throat), unusual bleeding or bruising, or excessive fatigue.
Pregnancy and Breastfeeding
Valcyte should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. Animal studies have demonstrated that ganciclovir is teratogenic (causes birth defects) and embryotoxic (harmful to the developing embryo). If you are pregnant, think you may be pregnant, or are planning to become pregnant, you must inform your doctor before starting treatment.
Women of childbearing potential must use effective contraception during treatment with Valcyte and for at least 30 days after the last dose. Male patients whose partners may become pregnant must use condoms during treatment and for at least 90 days after stopping Valcyte, as ganciclovir has been shown to cause impaired fertility and may be present in semen.
Valcyte is contraindicated during breastfeeding. If treatment with Valcyte is deemed necessary, breastfeeding must be discontinued before therapy begins.
Studies in animals have shown that ganciclovir can cause temporary or permanent inhibition of spermatogenesis (sperm production). Male infertility has been reported as an uncommon side effect. Discuss fertility preservation options with your doctor before starting treatment if this is a concern.
Driving and Operating Machinery
Valcyte may cause side effects such as dizziness, fatigue, tremor, and confusion that can impair your ability to drive or operate machinery safely. Do not drive or use tools or machines if you experience any of these symptoms while taking this medication. You are personally responsible for assessing your fitness to perform these activities.
How Does Valcyte Interact with Other Drugs?
Valcyte can interact with many medications, particularly those that affect the bone marrow, kidneys, or immune system. Important interactions include imipenem-cilastatin (seizure risk), antiretroviral drugs (altered blood levels), and immunosuppressants used after transplantation. Always tell your doctor about all medications you are taking.
Drug interactions with valganciclovir/ganciclovir can be clinically significant and may result in altered drug levels, increased toxicity, or reduced efficacy of either medication. Because ganciclovir is primarily eliminated through the kidneys, drugs that reduce kidney function or compete for renal tubular secretion can increase ganciclovir blood levels and the risk of toxicity. Similarly, drugs that suppress bone marrow function may have additive myelosuppressive effects when combined with Valcyte.
It is essential to inform your doctor or pharmacist about all medications you are currently taking, have recently taken, or plan to take, including over-the-counter medicines, herbal supplements, and vitamins.
Major Interactions
| Drug | Category | Interaction Effect | Clinical Significance |
|---|---|---|---|
| Imipenem-cilastatin | Antibiotic | Increased risk of seizures when taken with Valcyte | Avoid combination unless benefit outweighs risk |
| Zidovudine (AZT) | Antiretroviral (HIV) | Both drugs cause bone marrow suppression; additive hematologic toxicity | Close blood count monitoring required |
| Didanosine | Antiretroviral (HIV) | Didanosine levels may increase significantly (up to 111%) | Monitor for didanosine toxicity (pancreatitis, neuropathy) |
| Mycophenolate mofetil | Immunosuppressant | Additive bone marrow suppression; both renally excreted, levels may increase | Frequent blood count monitoring essential |
Other Notable Interactions
| Drug | Category | Interaction Effect |
|---|---|---|
| Probenecid | Gout medication | Reduces renal clearance of ganciclovir; blood levels may increase by up to 40% |
| Ciclosporin / Tacrolimus | Immunosuppressants | May increase nephrotoxicity; monitor kidney function closely |
| Trimethoprim / Sulfamethoxazole | Antibiotic | Additive bone marrow suppression; increased hematologic toxicity risk |
| Dapsone | Antibiotic / Antiprotozoal | Additive bone marrow suppression |
| Pentamidine | Antiparasitic / Antipneumocystis | Additive bone marrow suppression and nephrotoxicity |
| Flucytosine / Amphotericin B | Antifungals | Additive bone marrow and/or renal toxicity |
| Vincristine / Vinblastine / Doxorubicin | Chemotherapy | Additive bone marrow suppression; enhanced myelotoxicity |
| Tenofovir | Antiretroviral (HIV/HBV) | Both renally eliminated; monitor for increased toxicity of either drug |
Valcyte should be taken with food to maximize absorption. When taken with a high-fat meal, the bioavailability of valganciclovir increases significantly. If you are unable to eat for any reason, you should still take Valcyte at the scheduled time, but inform your doctor if this becomes a recurring issue.
What Is the Correct Dosage of Valcyte?
The standard adult dose for CMV prevention after transplantation is 900 mg once daily for 100 days (or 200 days for kidney transplants). For CMV retinitis treatment, the induction dose is 900 mg twice daily for 21 days, followed by 900 mg once daily maintenance. Doses must be reduced in patients with impaired kidney function.
Valcyte dosing varies depending on the clinical indication, patient age, weight, and kidney function. It is critical to follow your doctor's dosing instructions precisely, as both underdosing (which may lead to treatment failure and viral resistance) and overdosing (which increases the risk of serious toxicity) must be avoided. Always take Valcyte with food.
Adults
CMV Prevention After Organ Transplantation
Treatment should begin within 10 days of transplantation. The recommended dose is 900 mg (two 450 mg tablets) taken once daily with food. For the oral solution, this corresponds to two doses of 9 ml each (total 18 ml = 900 mg). Treatment should continue for 100 days after transplantation. For kidney transplant recipients, the doctor may extend treatment to 200 days.
CMV Retinitis Treatment – Induction Phase
The recommended induction dose is 900 mg taken twice daily (morning and evening with food) for 21 days (3 weeks). Using the oral solution, this means two doses of 9 ml (450 mg) taken twice daily. Do not continue induction treatment beyond 21 days unless specifically instructed by your doctor, as this increases the risk of side effects.
CMV Retinitis Treatment – Maintenance Phase
After the 21-day induction phase, the maintenance dose is 900 mg taken once daily with food. Try to take the medication at the same time each day. Your doctor will determine how long maintenance therapy should continue. If the retinitis worsens during maintenance, your doctor may reinstitute induction therapy or switch to an alternative CMV treatment.
Children and Adolescents
Valcyte is approved for CMV prevention in pediatric organ transplant recipients. Treatment should begin within 10 days of transplantation and continue for 100 days (or up to 200 days for kidney transplants). Unlike adults, the dose for children is not fixed – it is calculated individually based on the child's body surface area (height and weight) and kidney function (creatinine clearance). Your child's doctor will determine the most appropriate dose.
The oral solution formulation (50 mg/ml) is particularly useful for pediatric dosing, as it allows precise measurement using the provided dosing syringes. The maximum dose for children should not exceed the equivalent adult dose of 900 mg.
Elderly Patients
The safety and efficacy of Valcyte have not been specifically studied in elderly patients. Because kidney function naturally declines with age, elderly patients are more likely to require dose adjustments based on their creatinine clearance. Close monitoring of kidney function and blood counts is particularly important in this population.
Patients with Kidney Problems
If your kidneys are not functioning at full capacity, your doctor will prescribe a reduced dose of Valcyte. The dose adjustment is based on your creatinine clearance (a measure of kidney function). It is extremely important that you take exactly the dose prescribed, as overdosing in patients with impaired kidney function can lead to serious and potentially irreversible toxicity, including severe bone marrow suppression and renal failure. Your blood counts and kidney function will need to be monitored more frequently during treatment.
Missed Dose
If you forget to take a dose of Valcyte, take it as soon as you remember. Then take your next dose at the usual scheduled time. Do not take a double dose to make up for a missed dose, as this increases the risk of serious side effects.
Overdose
If you take more Valcyte than prescribed, or if a child accidentally ingests the medication, seek medical attention immediately by contacting your doctor, going to the nearest emergency department, or calling your local poison control center. Overdose with Valcyte can cause serious adverse effects, particularly bone marrow suppression (dangerously low blood cell counts) and kidney damage. Hospital admission may be necessary for monitoring and supportive care. Hemodialysis and adequate hydration may help reduce ganciclovir blood levels.
Handle Valcyte oral solution carefully. Avoid getting the solution on your skin or in your eyes. If skin contact occurs, wash the area thoroughly with soap and water. If eye contact occurs, rinse your eyes thoroughly with clean water. Always use the provided dosing syringe to measure your dose accurately. Two syringes are included in each package – replace each syringe after 20 uses. Shake the bottle well for about 5 seconds before each use.
What Are the Side Effects of Valcyte?
The most significant side effects of Valcyte involve bone marrow suppression, causing low white blood cell counts (neutropenia), low red blood cell counts (anemia), and low platelet counts. Other common side effects include diarrhea, nausea, vomiting, headache, fatigue, and fever. Seek immediate medical attention if you experience signs of severe infection, unusual bleeding, or allergic reactions.
Like all medicines, Valcyte can cause side effects, although not everyone will experience them. Some side effects are serious and require immediate medical attention, while others are mild and temporary. The frequency and severity of side effects can vary depending on the dose, duration of treatment, underlying medical conditions, and concomitant medications.
In rare cases (up to 1 in 1,000 people), a sudden and severe allergic reaction (anaphylaxis) may occur. Stop taking Valcyte and seek emergency medical help immediately if you experience: progressive itchy rash (hives), sudden swelling of the throat, face, lips, or mouth causing difficulty swallowing or breathing, or sudden swelling of hands, feet, or ankles.
Very Common
May affect more than 1 in 10 people
- Low white blood cell count (neutropenia) – signs include sore throat, mouth sores, fever
- Low red blood cell count (anemia) – signs include shortness of breath, fatigue, palpitations, pale skin
- Oral thrush (candidiasis)
- Upper respiratory tract infection (e.g., sinusitis, tonsillitis)
- Loss of appetite
- Headache
- Cough
- Shortness of breath
- Diarrhea
- Nausea or vomiting
- Abdominal pain
- Eczema
- Fatigue
- Fever
Common
May affect up to 1 in 10 people
- Sepsis (blood poisoning) – signs include fever, chills, rapid heartbeat, confusion
- Low platelet count (thrombocytopenia) – signs include easy bruising, blood in urine or stool, bleeding gums
- Severely low blood counts (pancytopenia)
- Pancreatitis – signs include severe abdominal pain radiating to the back
- Seizures
- Influenza, urinary tract infection, skin infections
- Depression, anxiety, confusion, sleep disturbances
- Numbness or tingling in hands/feet, taste changes
- Eye inflammation (conjunctivitis), eye pain, vision problems
- Ear pain
- Low blood pressure, difficulty swallowing
- Constipation, bloating, indigestion, mouth sores
- Abnormal liver or kidney test results
- Night sweats, itching, skin rash, hair loss
- Back pain, muscle or joint pain, muscle cramps
- Weight loss, chills, malaise
Uncommon
May affect up to 1 in 100 people
- Bone marrow failure
- Hallucinations – hearing or seeing things that are not real
- Abnormal thoughts or feelings, loss of contact with reality
- Impaired kidney function
- Agitation, tremors
- Deafness
- Irregular heart rhythm
- Hives (urticaria), dry skin
- Blood in urine
- Male infertility
- Chest pain
Rare
May affect up to 1 in 1,000 people
- Anaphylactic shock (severe allergic reaction)
- Retinal detachment (reported only in AIDS patients treated for CMV retinitis)
The side effects reported in children and adolescents are similar to those seen in adults. If you notice any side effects not listed here, or if any side effect becomes severe, contact your doctor, pharmacist, or nurse.
If you experience any side effects, including those not mentioned here, please report them to your healthcare provider. Reporting side effects helps to continuously monitor the benefit-risk balance of medications. You can also report suspected adverse reactions to your national pharmacovigilance authority (e.g., the FDA MedWatch program in the US, the Yellow Card Scheme in the UK, or the EMA EudraVigilance system in Europe).
How Should You Store Valcyte?
Valcyte tablets require no special storage conditions. The reconstituted oral solution must be stored in a refrigerator at 2–8°C (36–46°F) and used within 49 days of preparation. Keep all forms of Valcyte out of the sight and reach of children.
Proper storage of Valcyte is essential to ensure the medication remains effective and safe to use throughout the treatment period. Always check the expiration date on the packaging before use. The expiration date refers to the last day of the stated month.
- Tablets (powder before reconstitution): No special storage requirements. Store at room temperature in the original packaging.
- Reconstituted oral solution: Must be refrigerated at 2–8°C (36–46°F). The oral solution has a shelf life of 49 days after reconstitution. Your pharmacist will write the preparation date on the bottle. Do not use the solution after this 49-day period.
- General precautions: Keep out of the sight and reach of children. Do not dispose of medicines in wastewater or household waste. Return unused medications to your pharmacy for safe disposal to protect the environment.
What Does Valcyte Contain?
The active substance is valganciclovir (as hydrochloride). Each milliliter of reconstituted oral solution contains 50 mg of valganciclovir. The solution also contains inactive ingredients including povidone, fumaric acid, sodium benzoate (E211), saccharin sodium, mannitol, and tutti-frutti flavoring.
After reconstitution of the powder with water, each 1 ml of Valcyte oral solution contains 55 mg of valganciclovir hydrochloride, equivalent to 50 mg of valganciclovir. The glass bottle contains 12 g of powder, which when reconstituted yields 100 ml of solution with a usable volume of 88 ml.
The inactive ingredients (excipients) in the oral solution include:
- Povidone – a binding agent
- Fumaric acid – a pH-adjusting agent
- Sodium benzoate (E211) – a preservative. The solution contains 1 mg/ml sodium benzoate. Benzoate salts may increase the risk of jaundice in newborns (up to 4 weeks of age).
- Saccharin sodium – a sweetener
- Mannitol – a bulking agent
- Tutti-frutti flavoring – containing maltodextrins (corn), propylene glycol, acacia gum (E414), and natural-identical flavoring agents (primarily banana, pineapple, and peach flavors)
The reconstituted solution is clear and colorless to brown in appearance. The package includes a bottle adapter and 2 dosing syringes graduated up to 10 ml (500 mg) with markings in 0.5 ml (25 mg) intervals.
Valcyte oral solution contains a total of 0.188 mg/ml of sodium, making it essentially "sodium-free." This is relevant for patients on a sodium-restricted diet.
What Happens If You Stop Taking Valcyte?
Do not stop taking Valcyte without consulting your doctor first. Stopping treatment prematurely may allow CMV to reactivate and multiply, potentially leading to serious organ damage or vision loss. Your doctor will determine the appropriate duration of therapy based on your individual clinical situation.
For transplant recipients receiving Valcyte prophylaxis, the full course of treatment (typically 100 to 200 days) is necessary to adequately protect against CMV disease during the period of highest risk. Premature discontinuation may leave you vulnerable to CMV reactivation at a time when your immune system is still significantly suppressed by anti-rejection medications.
For patients with CMV retinitis, stopping maintenance therapy without medical guidance can lead to recurrence of the retinal infection and progressive vision loss. Your ophthalmologist will monitor your retinal status and advise you on the appropriate duration of treatment. In some cases, lifelong maintenance therapy may be necessary if immune reconstitution has not been achieved.
Frequently Asked Questions About Valcyte
Valcyte (valganciclovir) is a prodrug of ganciclovir. Once taken by mouth, valganciclovir is rapidly converted to ganciclovir in the body. The primary advantage of valganciclovir is its significantly better oral bioavailability – approximately 60% compared to only about 6% for oral ganciclovir. This means valganciclovir achieves therapeutic blood levels comparable to intravenous ganciclovir when taken orally, enabling effective outpatient treatment without the need for intravenous administration.
While there is no specific interaction between Valcyte and alcohol listed in prescribing information, it is generally advisable to limit or avoid alcohol during treatment. Both Valcyte and alcohol can cause fatigue, dizziness, and affect liver function. Additionally, alcohol can weaken the immune system, which may counteract the therapeutic goals of Valcyte treatment. Always discuss alcohol consumption with your doctor.
For CMV prophylaxis after organ transplantation, Valcyte is typically prescribed for 100 days. However, for kidney transplant recipients, many transplant centers now recommend an extended course of 200 days, as clinical studies have shown that longer prophylaxis reduces the incidence of late-onset CMV disease. Your transplant team will determine the optimal duration based on your specific risk profile, including the CMV serostatus of both the donor and recipient.
Low white blood cell count (neutropenia) is one of the most common and potentially serious side effects of Valcyte. If your blood test shows a significantly low neutrophil count (absolute neutrophil count below 500 cells/mm³), your doctor may temporarily suspend treatment, reduce the dose, or add a growth factor medication (such as G-CSF or filgrastim) to stimulate white blood cell production. Do not adjust your dose on your own – always follow your doctor's instructions and attend all scheduled blood monitoring appointments.
Valcyte is specifically approved only for CMV infections – CMV retinitis in AIDS patients and CMV prophylaxis after organ transplantation. While ganciclovir (the active metabolite) has in vitro activity against other herpes viruses, Valcyte is not approved or recommended for treating conditions like herpes simplex, varicella-zoster, or Epstein-Barr virus infections. Other antiviral medications with more favorable risk-benefit profiles are available for those conditions. Always use Valcyte only as prescribed by your doctor.
Yes, generic versions of valganciclovir are available in many countries. Common generic brands include Valganciclovir Orion and Valganciclovir Bluefish, among others. Generic versions contain the same active ingredient (valganciclovir) and must meet the same regulatory standards for quality, safety, and efficacy as the original branded product. Your doctor or pharmacist can advise you on whether a generic alternative is appropriate for your situation.
References
All medical information on this page is based on internationally recognized medical guidelines, regulatory documents, and peer-reviewed research. The following sources were consulted:
- European Medicines Agency (EMA). Valcyte Summary of Product Characteristics (SmPC). Last updated 2024. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration (FDA). Valcyte (valganciclovir hydrochloride) Prescribing Information. Genentech/Roche. Available at: www.accessdata.fda.gov
- Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-Organ Transplantation. Transplantation. 2018;102(6):900-931. doi:10.1097/TP.0000000000002191
- Humar A, Limaye AP, Blumberg EA, et al. Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients Is Associated with Long-Term Reduction in Cytomegalovirus Disease. Transplantation. 2010;90(12):1427-1431.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023. Available at: www.who.int
- British National Formulary (BNF). Valganciclovir. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- Martin DF, Sierra-Madero J, Walmsley S, et al. A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus Retinitis. N Engl J Med. 2002;346(15):1119-1126. doi:10.1056/NEJMoa011759
- Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients – Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians and pharmacists with expertise in infectious diseases, transplant medicine, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international medical guidelines from the EMA, FDA, WHO, and BNF.
All medical claims are supported by peer-reviewed research and international clinical guidelines. Evidence level: 1A (systematic reviews and meta-analyses of RCTs).
iMedic receives no pharmaceutical funding. All content is independently researched and reviewed without commercial influence.
This article is reviewed and updated regularly to reflect the latest clinical evidence and regulatory changes.
Written for patients and caregivers in clear, accessible language. WCAG 2.2 AAA compliant for universal accessibility.